
Over 12 lakh qualify NEET UG 2025, but only 1.18 lakh MBBS seats available
This year, the National Testing Agency (NTA) has declared that out of 22.09 lakh students who appeared, 12.36 lakh have cleared the exam -- slightly fewer than the 13.15 lakh who qualified last year.That's slightly more than half of all candidates clearing one of the most competitive entrance exams in the country. However, the next hurdle is steeper: securing an MBBS seat.advertisementAs per the National Medical Commission (NMC)'s revised UG seat matrix for 2025-26, there are a total of 1,18,190 MBBS seats available across 780 medical colleges (both government and private) in India. These include institutions like AIIMS, JIPMER, and state-run as well as private colleges.
That means nearly 12 lakh qualified students will not get an MBBS seat, unless they choose to study abroad or consider alternate medical or allied health pathways.TOP 5 STATES WITH THE HIGHEST MBBS SEATSHere are the five states with the largest share of MBBS seats in the country, according to the NMC's UG seat matrix 2024-25 PDF:Tamil Nadu: 11,725 seatsUttar Pradesh: 11,225 seatsKarnataka: 11,045 seatsMaharashtra: 10,595 seatsTelangana: 8,540 seatsTogether, these five states contribute over 53,000 seats, which is nearly 45% of the national total.STATES WITH THE LOWEST MBBS SEATSadvertisementSome states and union territories continue to struggle with medical infrastructure, offering very few MBBS seats to local aspirants:Arunachal Pradesh: 50 seatsMeghalaya: 50 seatsAndaman & Nicobar Islands: 114 seatsDadra & Nagar Haveli: 177 seatsSikkim: 150 seatsIn some of these regions, government medical seats are extremely limited, so students often rely on private colleges within the state or look to other states for more affordable options.FEE DIFFERENCE BETWEEN GOVERNMENT AND PRIVATE MEDICAL COLLEGESIf you're one of the students hoping to bag an MBBS seat this year, the cost of medical education is going to be a major factor, especially if you're eyeing private colleges due to limited government seats.Here's a rough comparison to give you an idea of what students and families are up against:Government medical colleges:These colleges are heavily subsidised and remain the most affordable route into the medical profession.Annual tuition: Rs 20,000 to Rs 1,50,000Total 5.5-year MBBS cost: Rs 1 lakh to Rs 7 lakhPrivate medical colleges:These include privately run institutions and deemed universities. The fees vary widely, but most fall on the higher end of the spectrum.Annual tuition: Rs 10 lakh to Rs 25 lakhadvertisementTotal MBBS cost: Rs 50 lakh to Rs 1.25 croreDeemed universities:These operate under a different regulatory category and often charge the highest tuition among private institutions.AIIMS and JIPMER:If you're lucky enough to get into one of the elite government institutes like AIIMS or JIPMER, you'll pay under Rs 10,000 per year, making it one of the most affordable MBBS pathways in the country.MEDICAL SEAT EXPANSION IN RECENT YEARSThe government has been steadily increasing MBBS seats across India:In 2014, India had 51,000 MBBS seats and 387 colleges.By 2023, this number had more than doubled to 1.07 lakh seats and 706 colleges.In 2024-25, the number now stands at 1,18,190 seats across 780 colleges.This includes the expansion of AIIMS institutions under the Pradhan Mantri Swasthya Suraksha Yojana (PMSSY), and the addition of both government and private medical colleges in underserved districts.According to the Ministry of Health and Family Welfare, this push aims to improve the doctor-population ratio and reduce regional healthcare disparities.Still, seat availability is uneven, with some states still lacking even a single government medical college.MEDICAL COUNSELLING TO GIVE FINAL WORDWith almost 13 lakh qualified students and just 1.18 lakh MBBS seats, the numbers speak for themselves. Despite the surge in medical education infrastructure, the demand far outpaces availability.advertisementFor aspirants, this means the competition is far from over. Centralised counselling will now decide who gets to join the country's limited list of future doctors.For others, it may be time to consider alternate courses, private institutions, or even medical education abroad.Check out the detailed UG medical seat matrix 2025-26 released by the NMC here.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Print
32 minutes ago
- The Print
Denied ambulance, tribal man travels 90 km on ST bus with newborn daughter's body in carry bag
'I lost my child due to the negligence and apathy of the health system,' muttered Sakharam who couldn't get an ambulance to shift his wife, who went into labor, to Khodala PHC on June 11. Denied ambulance by Nashik Civil Hospital, the tribal man travelled on a state transport bus, carrying the body of his stillborn daughter home in a carry bag. Mumbai, Jun 16 (PTI) Sakharam Kavar's voice trembled with deep anguish and helplessness as he recalled the 90-km agonising journey no parent should endure. The 28-year-old daily wage labourer from the Katkari tribal community lives in a hut in Jogalwadi hamlet in Palghar district, around 200 km from Mumbai. Until recently, he and his wife Avita, 26, worked at a brick kiln in Badlapur in Thane district with their two children. With their third child due soon, they returned to their village three weeks ago in hopes of a safe delivery. But on June 11, when Avita went into labor, their ordeal began. 'We called for an ambulance since morning, but no one came,' Sakharam said. The village ASHA worker was initially unavailable. When she tried calling the emergency number 108, she reportedly received no response initially but later arranged a private vehicle to take Avita to Khodala Public Health Centre. 'There was movement in my womb on the way,' Avita said, adding that she was kept waiting for more than an hour after reaching the PHC. She was later referred to Mokhada Rural Hospital. 'They isolated me in a room. When my husband protested, they called the police, who beat him,' she alleged. Doctors at Mokhada advised a transfer to Nashik Civil Hospital after they couldn't record the heartbeats of the foetus. Since the ambulance was unavailable, an ambulance was summoned from Aase village, 25 km away. Avita reached Nashik late in the evening where she delivered a stillborn baby girl around 1:30 a.m. on June 12. In the morning, the hospital handed over the baby's body to Sakharam, but refused an ambulance to take the body home. 'I went to the ST stand, bought a Rs 20 carry bag, wrapped my baby in cloth, and travelled nearly 90 kilometres in an MSRTC bus,' he said. 'Nobody asked what I was carrying.' The baby was buried in their village the same day. On June 13, Sakharam returned to Nashik to bring his wife home. 'They again refused an ambulance,' he claimed. Weak and recovering, Avita made the journey back by bus. 'They didn't even give her any medicine,' Sakharam added. Dr. Bhausaheb Chattar of Mokhada Rural Hospital confirmed the sequence of events. 'The baby was dead in the womb. The ambulance at our centre had broken down, so we arranged one from Aase. He indeed travelled with the baby's body on a bus,' he told PTI. Chattar also claimed the hospital had offered an ambulance for the return trip, but Sakharam allegedly refused and signed a waiver—something the father denies. He said all possible assistance was provided to the tribal couple. 'I lost my child because of their neglect,' Sakharam said quietly. PTI DC NSK This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.


Business Standard
35 minutes ago
- Business Standard
Zydus Life subsidiary ZHL appoints Swati Dalal as MD
Zydus Lifesciences announced that its subsidiary, Zydus Healthcare, has appointed Swati Dalal as additional director and MD for a five-year term, effective 16 June 2025. The appointment was approved by the nomination and remuneration committee (NRC). Swati Dalal is part of the senior management team at Zydus Lifesciences and brings extensive leadership experience to her new role as Managing Director of Zydus Healthcare. Swati Dalal is a seasoned commercial leader with over 30 years of rich and diverse experience in the healthcare and pharmaceutical industry. She began her career with Wockhardt Nutrition before moving to the erstwhile Boots, where she continued through successive mergers with Knoll, Solvay, and Abbott, progressively taking on leadership roles across the organisation. During her tenure at Abbott, she held various senior positions across both commercial and support functions. These included commercial director sales & marketing, as well as leadership of new product introductions (NPI), business development, and commercial excellence. She later served as managing director of Abbott Nutrition and Abbott Primary Care, and most recently, as managing director of Abbott India. Swati has also been a strong proponent of employee development and inclusion. She has led and contributed to initiatives such as women leaders of Abbott, the early career network, and has actively championed Abbotts diversity, equity, and inclusion (DEI) agenda in India. Swati holds a pharmacy degree from P.K.M. Kundnani College of Pharmacy, Mumbai and a post-graduate degree in Management Studies from Jamnalal Bajaj Institute of Management Studies in Mumbai. Swati Dalal is not related to any of the directors of Zydus Lifesciences or its wholly owned subsidiary, Zydus Healthcare. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. Shares of Zydus Lifesciences shed 0.51% to Rs 970 on the BSE.


Business Standard
37 minutes ago
- Business Standard
Lupin inks licensing deal with Sino Universal pharma for Tiotropium DPI drug in China
Lupin announced that it has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for the commercialization of Tiotropium Dry Powder Inhaler (DPI) capsules in China for the treatment of chronic obstructive pulmonary disease. As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorization holder and responsible for manufacturing the product. Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions. This partnership will enable Lupin to expand its footprint in China, ensuring that patients have timely access to innovative and high-quality healthcare solutions, considering the increasing prevalence of respiratory conditions. Fabrice Egros, president of corporate development, Lupin, said, "We are very pleased to partner with SUP to bring Tiotropium DPI to patients in China. This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector. SUP is our esteemed partner in this endeavor, and together we aim to enhance patient access to innovative and high-quality healthcare solutions. Wang Li, president of SUP, said, "We are truly honored to partner with Lupin, a global pharmaceutical leader, on Tiotropium DPI. Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care. By bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health." Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.05% to Rs 2,001.45 on the BSE.